###begin article-title 0
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 78 81 <span type="species:ncbi:9606">men</span>
###xml 86 91 <span type="species:ncbi:9606">women</span>
Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 356 358 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-</italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 459 466 <span type="species:ncbi:4097">tobacco</span>
###xml 707 714 <span type="species:ncbi:4097">tobacco</span>
Cigarette smoking is an established risk factor for bladder cancer. Epidemiological and biological data suggest that genetic polymorphisms in activating and detoxifying enzymes may play a role in determining an individual's susceptibility to bladder cancer in particular when in combination with specific environmental exposures such as cigarette smoking. N-acetyltransferase (NAT) enzymes, NAT1 and NAT2, are involved in the activation and detoxification of tobacco smoke constituents. Polymorphisms in these genes alter the ability of these enzymes to metabolize carcinogens, as certain allelic combinations result in a slow or rapid acetylation phenotype. Glutathione S-transferases (GSTs) also detoxify tobacco smoke constituents, and polymorphisms within the GSTM1 and GSTT1 genes can result in a complete lack of enzyme activity.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 452 455 <span type="species:ncbi:9606">men</span>
###xml 460 465 <span type="species:ncbi:9606">women</span>
We assessed the association between common polymorphisms identified in the GSTM1, GSTT1, NAT1, and NAT2 genes and the risk of bladder cancer in two nested case-control studies within the Nurses' Health Study (n = 78 female cases, 234 female controls) and the Health Professionals' Follow-up Study (n = 139 male cases, 293 male controls). We also evaluated whether cigarette smoking modified the associations of the genotypes and bladder cancer risk in men and women.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 119 122 <span type="species:ncbi:9606">men</span>
###xml 127 132 <span type="species:ncbi:9606">women</span>
Overall, we observed no statistically significant associations between the polymorphisms and bladder cancer risk among men and women, although given our sample size, we had limited power to detect small to moderate effects. There was however the suggestion of an increased risk among female ever smokers with the NAT2 slow genotype and an increased risk in male never smokers with the GSTM1 null genotype.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
In summary, these prospective results are consistent with previous literature supporting associations between bladder cancer and the NAT2 slow acetylation and the GSTM1 null genotypes.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-</italic>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 452 457 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 466 498 466 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3, NAT1*4, NAT1*10, NAT*11 </italic>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 535 557 535 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5, NAT2*6, NAT2*7</italic>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 637 642 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 740 745 740 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 947 952 947 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 1084 1089 1084 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 1133 1135 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1173 1181 1173 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 1232 1233 1232 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1307 1309 1307 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1374 1379 1374 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 1446 1448 1446 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1449 1451 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1602 1604 1602 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1605 1607 1605 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1608 1610 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1611 1613 1611 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 147 154 <span type="species:ncbi:4097">tobacco</span>
Cigarette smoking is the predominant risk factor for bladder cancer in males and females [1-5]. Carcinogens such as aminobiphenyls (ABPs) found in tobacco have been implicated in bladder cancer etiology in smokers [6]. N-acetyltransferase (NAT) enzymes, NAT1 and NAT2, are involved in the metabolism of these carcinogens via O- and N- acetylation [7]. NAT2 and NAT1 are involved in the detoxification and bioactivation of carcinogens [8,9]. Four major NAT1 alleles, NAT1*3, NAT1*4, NAT1*10, NAT*11 [10], and three common NAT2 alleles, NAT2*5, NAT2*6, NAT2*7, have been identified in Caucasian populations [7]. Individuals homozygous for NAT2 rapid acetylator alleles are classified as rapid-acetylator phenotype; individuals homozygous for NAT2 slow acetylator alleles are classified as slow-acetylator phenotype, and heterozygous individuals (one rapid and one slow acetylator alleles) are classified as the intermediate phenotype [11]. The slow NAT2 acetylation genotype compromises its detoxification ability, and studies have consistently observed an association between the slow NAT2 genotype and increased bladder cancer risk [11-13]. The presence of one copy of the NAT1*10 allele has been associated with a rapid phenotype [8,10] however a more recent study does not support these earlier findings [14]. Several studies have investigated the association between the NAT1 variant alleles and bladder cancer risk with inconsistent results [14-20]. Fewer studies however have formally evaluated whether the relationship of cigarette smoking and bladder cancer risk differed by acetylation status [11,16,18-20].
###end p 11
###begin p 12
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g. </italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 614 620 614 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 624 630 624 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 822 828 822 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 832 838 832 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 915 921 915 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1093 1099 1093 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1169 1171 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 371 378 <span type="species:ncbi:4097">tobacco</span>
###xml 734 741 <span type="species:ncbi:4097">tobacco</span>
Glutathione S-transferases (GSTs) are involved in the metabolism of environmental carcinogens, reactive oxygen species, and chemotherapeutic agents by catalyzing reactions between glutathione and electrophilic compounds [21,22]. Glutathione S-transferase M1 (GSTM1) is involved in the detoxification of polycyclic aromatic hydrocarbons (PAHs) and benzo(a)pyrene found in tobacco smoke [23,24]. Glutathione S-transferase T1 (GSTT1) is involved in activation and detoxification reactions and catalyzes the conjugation of industrial chemicals, e.g. ethylene oxides, with glutathione [25]. Homozygous deletions of the GSTM1 and GSTT1 genes are common and result in a complete loss of enzyme activity [22,26,27]. Because the metabolism of tobacco-related carcinogens may be influenced by the activity of GSTs, polymorphisms in GSTM1 and GSTT1 may modify the risk of bladder cancer associated with these carcinogens. The GSTM1 null polymorphism has been consistently associated with an increased risk of bladder cancer in pooled and meta-analyses [11,23,28]. Studies investigating the importance of GSTT1 in bladder carcinogenesis are more limited and inconsistent [19,24,29-35].
###end p 12
###begin p 13
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 18 25 <span type="species:ncbi:4097">tobacco</span>
###xml 709 714 <span type="species:ncbi:9606">women</span>
###xml 798 801 <span type="species:ncbi:9606">men</span>
Since exposure to tobacco smoke carcinogens is a risk factor for bladder cancer, genetic modulation of carcinogen metabolism may explain some inter-individual bladder cancer susceptibility. Given their biological role, polymorphisms within the GSTT1, GSTM1, NAT1, and NAT2 genes may be important in determining an individual's susceptibility to bladder cancer. Recent studies have also suggested that although the risk associated with each variant may be small, in combination with other genetic and/or environmental factors, the effects of the polymorphisms may be increased. We examined the associations between polymorphisms within these key genes and bladder cancer risk in a nested case-control study of women participating in the Nurses' Health Study (NHS) and a nested case-control study of men participating in the Health Professionals' Follow-Up Study (HPFS). Furthermore, we assessed the potential for effect modification by cigarette smoking for the associations between the genotypes and bladder cancer risk.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Nurses' Health Study
###end title 15
###begin p 16
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 341 346 <span type="species:ncbi:9606">women</span>
The NHS began in 1976 when 121,700 female United States registered nurses aged 30-55 years completed a self-administered questionnaire. Detailed information on individual characteristics and behaviors was obtained from the questionnaires at baseline and biennially thereafter. Between 1989 and 1990, blood samples were collected from 32,826 women; follow-up for this subcohort exceeds 96%. The methods used for blood collection have been previously detailed [36].
###end p 16
###begin title 17
Case-control study
###end title 17
###begin p 18
###xml 1407 1409 1407 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1410 1412 1410 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1439 1441 1439 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1561 1566 1561 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 1766 1768 1766 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1793 1799 1793 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1803 1809 1803 1809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 329 334 <span type="species:ncbi:9606">women</span>
###xml 780 792 <span type="species:ncbi:9606">participants</span>
###xml 1316 1321 <span type="species:ncbi:9606">women</span>
###xml 1946 1951 <span type="species:ncbi:9606">Human</span>
###xml 1980 1985 <span type="species:ncbi:9606">Women</span>
In our study, we included both incident and prevalent bladder cancer cases from the NHS blood cohort. Trained physicians who were blinded to exposure information reviewed hospital records and pathology reports. We were able to confirm approximately 95% of self-reported bladder cancer cases. Eligible incident cases consisted of women with confirmed bladder cancer that had been diagnosed anytime after blood collection (1989-90) and up to June 1, 2000, with no previously diagnosed cancer except for nonmelanoma skin cancer. Prevalent cases were defined as having confirmed bladder cancer diagnosed after questionnaire return in 1976 and before the date of blood collection, with no previously diagnosed cancer except for nonmelanoma skin cancer. Controls were randomly selected participants who had given a blood sample and were free of diagnosed cancer (except nonmelanoma skin cancer) up to and including the interval in which the case was diagnosed. Controls were matched to cases 3:1 according to year of birth, smoking status at blood draw (never versus ever), month of blood collection, and fasting status at blood draw (for possible plasma hormone analyses). This case-control study consists of 78 bladder cancer cases (47 incident cases and 31 prevalent cases), and 234 matched controls. In addition, 2646 women who were controls in either a nested case-control study of breast cancer (n = 1686) [37,38], colon cancer (n = 461) [39], and colon polyps (n = 499), were free of cancer other than nonmelanoma skin cancer, and were genotyped for the three NAT2 polymorphisms were included in unconditional logistic regression analyses to stabilize confidence intervals. A subset of the extra controls (n = 466) from the breast cancer nested case-control study [40] were genotyped for the GSTM1 and GSTT1 polymorphisms and included in the unconditional logistic regression analyses. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, MA. Completion of the self-administered questionnaire and receipt of the blood sample were considered to imply informed consent.
###end p 18
###begin title 19
Health professionals' follow-up study
###end title 19
###begin p 20
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 78 81 <span type="species:ncbi:9606">men</span>
###xml 219 222 <span type="species:ncbi:9606">men</span>
###xml 379 391 <span type="species:ncbi:9606">participants</span>
###xml 477 489 <span type="species:ncbi:9606">participants</span>
The HPFS is an ongoing prospective study of the causes of chronic diseases in men. The cohort began in 1986 when 51,529 U.S. male health professionals aged 40 to 75 years responded to a mailed questionnaire [41]. These men provided detailed information on medical histories and health-related exposures at baseline and biennial questionnaires thereafter. The follow-up for these participants is approximately 93%. Blood samples were collected between 1993 and 1995 from 18,025 participants. Approximately 95% of the samples arrived within 24 hours of blood draw.
###end p 20
###begin title 21
Case-control study
###end title 21
###begin p 22
###xml 1592 1597 1592 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 248 251 <span type="species:ncbi:9606">men</span>
###xml 701 713 <span type="species:ncbi:9606">participants</span>
###xml 1385 1388 <span type="species:ncbi:9606">men</span>
In our study, we included both incident and prevalent bladder cancer cases from the HPFS blood cohort. All cases in this analysis were confirmed through histopathologic reports reviewed by a study investigator. Eligible incident cases consisted of men with confirmed bladder cancer that had been diagnosed anytime after blood collection (1993-95) and up to June 1, 2000, with no previously diagnosed cancer except for nonmelanoma skin cancer. Prevalent cases were defined as having confirmed bladder cancer diagnosed after questionnaire return in 1986 and before the date of blood collection, with no previously diagnosed cancer except for nonmelanoma skin cancer. All controls were randomly selected participants who had given a blood sample and were free of diagnosed cancer (except nonmelanoma skin cancer) up to and including the interval in which the case was diagnosed. Controls were matched to cases 2:1 according to year of birth, smoking status at blood draw (current, past, or never), fasting status (for possible plasma hormone analyses), and month of sample collection. For cases accrued from 1998 to 2000, controls were matched to cases 3:1 with the previously described matching factors to increase our statistical power. This case-control study consists of 139 bladder cancer cases (91 incident cases and 48 prevalent cases), and 293 matched controls. In addition, 1028 men who were controls in either a nested case-control study of colon cancer (n = 321) or colon polyps (n = 707), were free of cancer other than nonmelanoma skin cancer, and were also genotyped for the three NAT2 polymorphisms were included in unconditional logistic regression analyses. Completion of the self-administered questionnaire and receipt of the blood sample were considered to imply informed consent.
###end p 22
###begin title 23
Sample collection
###end title 23
###begin p 24
Venous blood samples were separated into plasma, buffy coat, and red blood cells and stored in liquid nitrogen. Genomic DNA was extracted from 50 muL buffy coat diluted with 150 muL of PBS using the QIAGEN QIAmp (Qiagen, Inc., Chatsworth, CA) 96-spin blood protocol according to the manufacturer's instructions. Genomic DNA concentrations were calculated in 96-well format using PicoGreen technology (Molecular Probes, Eugene, OR).
###end p 24
###begin title 25
Genotyping methods
###end title 25
###begin p 26
###xml 96 107 96 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 I114T </italic>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R197Q </italic>
###xml 125 132 125 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*6A</italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G286E </italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*7A</italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 547 555 547 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*14 </italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G191A</italic>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 744 751 744 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A</italic>
###xml 753 760 753 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*6A</italic>
###xml 762 769 762 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*7A</italic>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 876 883 876 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
###xml 615 627 <span type="species:ncbi:9606">participants</span>
Genotyping was performed at the DFCI/Harvard Cancer Center High Throughput Genotyping Core. The NAT2 I114T (NAT2*5A), R197Q (NAT2*6A), and G286E (NAT2*7A) polymorphisms were genotyped by the 5' nuclease assay (Taqman) on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). A description of and methods for each NAT2 assay can be found at the National Cancer Institute SNP500Cancer website [42]. We did not genotype polymorphisms that are rare (defined as < 5% frequency) in Caucasian populations [7], such as the NAT2*14 allele (G191A) [43]. For consistency with previous studies, participants were classified as slow NAT2 acetylators if they were homozygous for any combination of the three slow acetylators (NAT2*5A, NAT2*6A, NAT2*7A)[11]. Rapid acetylators for NAT2 were defined as being either heterozygous or homozygous for the wildtype NAT2*4 allele.
###end p 26
###begin p 27
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3 </italic>
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C1095A</italic>
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 84 91 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C1095A </italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T1088</italic>
###xml 104 112 104 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14 </italic>
###xml 113 127 113 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G560A, T1088A </italic>
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C1095A</italic>
###xml 145 153 145 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11 </italic>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 385 393 385 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3</italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4</italic>
###xml 475 482 475 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11</italic>
###xml 488 496 488 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14 </italic>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 527 535 527 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
We genotyped four common NAT1 alleles, NAT1*3 (C1095A), NAT1*4 (wildtype), NAT1*10 (C1095A and T1088A), NAT1*14 (G560A, T1088A ,and C1095A), and NAT1*11 (deletion of nine nucleotides from 1080 to 1088) [15,44]. The NAT1*4 allele is the most common allele in all populations studied, and the homozygous NAT1*4 genotype has been associated with normal NAT1 acetylation activity [7]. The NAT1*10 allele is considered the putative rapid allele in comparison with NAT1*3, NAT1*4, NAT1*11, and NAT1*14 [10]. All individuals with the NAT1*10 genotype were classified as either homozygous or heterozygous rapid acetylators.
###end p 27
###begin p 28
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Genotypes for the GSTT1 and GSTM1 deletions were determined by polymerase chain reaction (PCR) using a previously published protocol [40]. In both assays, the absence of the PCR product was indicative of the null genotype; these assays do not distinguish between heterozygous or homozygous wildtype genotypes.
###end p 28
###begin p 29
All genotyping was performed by laboratory personnel blinded to case-control status, and blinded quality control samples were inserted to validate genotyping identification procedures; concordance for blinded samples was 100%.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 13 15 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 725 730 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. </italic>
###xml 1619 1623 1617 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 1625 1629 1623 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
###xml 1631 1636 1629 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 1642 1648 1640 1646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1669 1670 1667 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1671 1673 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1674 1676 1672 1674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1677 1679 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1680 1682 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1878 1884 1876 1882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1954 1960 1952 1958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 2030 2035 2028 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 2117 2125 2115 2123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 2249 2255 2247 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 2325 2331 2323 2329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 2401 2406 2399 2404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 2488 2496 2486 2494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 1856 1859 <span type="species:ncbi:9606">men</span>
###xml 2225 2230 <span type="species:ncbi:9606">women</span>
We used a chi2 test to assess whether the genotypes were in Hardy-Weinberg equilibrium and to determine P values for differences in genotype frequencies between cases and controls. The associations between the genotypes and bladder cancer risk were examined by using conditional and unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Unconditional logistic regression models assessing the main effect of the genotype on bladder cancer risk included the additional control groups to maximize the sample size, stabilize CIs, and to increase the power to detect meaningful associations. In addition to the matching factors, analyses were also adjusted for packyears of smoking (i.e. average reported number of cigarette packs smoked per day multiplied by the number of years of smoking). Inclusion of additional factors, e.g. geographic region, alcohol intake, cruciferous vegetable intake, did not substantially change the point estimates, and therefore these factors were not included in the final models. To test statistical interactions between the genotypes and cigarette smoking in unconditional models, we first used a likelihood-ratio test (LRT) to compare nested models that included terms for all combinations of the genotypes and cigarette smoking status to the models with indicator variables for the main effects only (nominal LRT). To test the statistical interaction between the various genotypes, a similar approach was employed. All p-values are two-sided. We used the SAS Version 8.2 software (SAS Institute, Cary, NC). Because the allele frequencies of NAT1, NAT2, GSTM1, and GSTT1 differ by ethnicity [7,23,24,45,46], all analyses were restricted to Caucasians. Numbers may vary for the different analyses due to missing genotype data. We had 80% power to detect the following ORs for the men: OR = 1.8 for the GSTM1 null genotype assuming a genotype prevalence of 50%; OR = 2.0 for the GSTT1 null genotype assuming a genotype prevalence of 15%; OR = 1.9 for the NAT2 slow acetylation genotype assuming a genotype prevalence of 62%; OR = 1.8 for the NAT1*10 carrier assuming a genotype prevalence of 35%. We had 80% power to detect the following ORs for the women: OR = 2.1 for the GSTM1 null genotype assuming a genotype prevalence of 50%; OR = 2.4 for the GSTT1 null genotype assuming a genotype prevalence of 15%; OR = 2.3 for the NAT2 slow acetylation genotype assuming a genotype prevalence of 62%; OR = 2.1 for the NAT1*10 carrier assuming a genotype prevalence of 35%.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
Population characteristics
###end title 33
###begin p 34
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Our study population included 78 bladder cancer cases and 234 matched controls from the NHS and 139 bladder cancer cases and 293 matched controls from the HPFS for a total of 217 bladder cancer cases and 526 matched controls. The risk factor profile for female bladder cancer cases and controls were similar with no statistically significant differences between cases and controls (Table 1). Similarly, no significant differences in risk factor distributions were observed in cases and controls in the HPFS (Table 1). Risk factor distributions between incident and prevalent cases in the NHS and incident and prevalent cases in the HPFS were also similar. A comparison of the population characteristics of the second control group with the first control group revealed no material differences in risk factor profiles in the NHS and HPFS.
###end p 34
###begin p 35
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 606 612 606 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 644 649 644 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 673 678 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 131 134 <span type="species:ncbi:9606">men</span>
###xml 139 144 <span type="species:ncbi:9606">women</span>
We compared the distributions of the GSTM1, GSTT1, NAT1, and NAT2 genotypes between incident and prevalent bladder cancer cases in men and women separately to determine whether the variant alleles were associated with survival. All of the genotype frequencies were similar among incident and prevalent cases in the NHS and in the HPFS (p > 0.2). Therefore, all incident and prevalent cases in each cohort were combined to form one case group for all statistical analyses. The genotype frequencies were in Hardy-Weinberg equilibrium for cases and controls. The allele frequencies among the controls for the GSTM1 null allele, GSTT1 null allele, NAT2 rapid genotype, and the NAT1 rapid genotype were similar to previously published reports in Caucasians [10,18,23,26,38,46,47]. Results from the conditional logistic regression analyses using only the matched dataset were similar to the results obtained from the unconditional analyses that included the additional controls.
###end p 35
###begin title 36
Nurses' Health Study
###end title 36
###begin p 37
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 152 158 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 704 710 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 714 720 714 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 427 432 <span type="species:ncbi:9606">women</span>
In the NHS, the prevalence of GSTM1 null genotype was similar among cases and controls (48.4% versus 52.5%, respectively, p = 0.54), in contrast to the GSTT1 null genotype, which was more prevalent in cases than controls (21.9% vs. 15.2%, respectively, p = 0.16). After adjusting for the matching factors and packyears of smoking, we observed no association between the GSTM1 and GSTT1 polymorphisms and bladder cancer risk in women (Table 2). We did not observe any statistically significant effect modification by cigarette smoking status for the GSTM1 and the GSTT1 null genotypes and bladder cancer risk (p for interaction > 0.30). Our results also do not support a gene-gene interaction between the GSTT1 and GSTM1 polymorphisms (p for interaction = 0.88).
###end p 37
###begin p 38
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 618 626 618 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
The frequency of the NAT2 slow acetylation genotype was similar among cases and controls (68.3% versus 62.1%, respectively, p = 0.32) (Table 3). The adjusted OR for the slow acetylation genotype compared to the rapid acetylation genotype was 1.33 (95% CI, 0.77-2.31). After stratification by cigarette smoking status, the association between NAT2 slow acetylation genotype and bladder cancer risk was stronger but not statistically significant among ever smokers (OR = 1.76; 95% CI, 0.88-3.52) (p for interaction = 0.15). We observed no significant association between bladder cancer risk and individuals carrying the NAT1*10 allele (Table 3), and no effect modification by cigarette smoking status for the NAT1 genotypes and bladder cancer risk (p for interaction > 0.10).
###end p 38
###begin title 39
Health professionals' follow-up study
###end title 39
###begin p 40
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 665 671 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 849 855 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
There were no significant differences in GSTM1 and GSTT1 genotype frequencies among cases and controls (p = 0.09 and 0.63, respectively), and no statistically significant associations between the GSTM1 and GSTT1 polymorphisms and bladder cancer risk in males (Table 2). We did observe a statistically significant interaction between the GSTM1 null genotype, cigarette smoking, and bladder cancer risk in males (p for interaction = 0.02). Among never smokers, the GSTM1 null genotype was associated with a statistically significant increased risk (OR = 3.23 (95% CI, 1.38, 7.58)), and among ever smokers, the OR was 0.96 (95% CI, 0.55-1.66). The association between GSTT1 polymorphism and bladder cancer risk remained similar after stratification by smoking status (p for interaction = 0.69), and no significant gene-gene interactions with GSTM1 and GSTT1 were detected (p for interaction = 0.22).
###end p 40
###begin p 41
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
The frequency of the NAT2 slow acetylation genotype was similar among cases and controls (57.3% versus 61.8%, p = 0.32) (Table 3). The adjusted OR for the slow acetylation genotype compared to the rapid acetylation genotype was 0.78 (95% CI, 0.53-1.15). We observed no significant association between bladder cancer risk and carrying the NAT1*10 allele (Table 3). Furthermore, we did not observe any statistically significant effect modification by cigarette smoking status for the NAT2 or NAT1 genotypes and bladder cancer risk (p for interaction > 0.4).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g. </italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 539 544 539 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
Evidence suggests that polymorphisms in activating and detoxifying enzymes may interact to effect the level of DNA damage sustained by a specific tissue and ultimately influence disease risk [47]. Therefore, imbalances between activation and detoxification processes may result in an increase in bladder cancer risk due to the accumulation of carcinogen metabolites, e.g. from cigarette smoking. Overall, in our population-based case-control study, we observed no statistically significant associations between the GSTT1, GSTM1, NAT1, and NAT2 polymorphisms and bladder cancer risk.
###end p 43
###begin p 44
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 641 646 641 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 982 990 982 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1150 1152 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1263 1271 1263 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 23 30 <span type="species:ncbi:4097">tobacco</span>
Aromatic amines within tobacco smoke are the most important class of bladder carcinogens [48]. These compounds may be partially responsible for the increased bladder cancer risk observed among slow NAT2 acetylators who have a decreased capacity to detoxify aromatic amines. Our data suggest an association between the NAT2 slow acetylation genotype and increased bladder cancer risk in female smokers. Our findings are biological plausible and are consistent with a recent study in Spain [11], which found that NAT2 slow acetylators have an increased risk of bladder cancer that was stronger for cigarette smokers compared to never smokers. NAT1 polymorphisms may also affect individual bladder cancer risk by interacting with cigarette smoking. Our findings do not support an association between the NAT1 polymorphisms, cigarette smoking, and bladder cancer; however we had little power to detect such an association. Additional studies that have assessed the relationship between NAT1*10 allele and bladder cancer risk have been inconsistent with some studies observing an increased risk [17,20], a decreased risk [15], or no association [11,16,18,19]. Larger epidemiological studies are required to clarify the relationship between bladder cancer risk and the NAT1*10 allele.
###end p 44
###begin p 45
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
We observed no significant associations with the GSTM1 polymorphism and bladder cancer risk, which is in contrast with previous findings [11,23]. The potential role of the GSTT1 polymorphism on bladder cancer susceptibility is less certain. Studies that have addressed the role of GSTT1 polymorphism and bladder cancer have been inconsistent. Of the published studies, some suggest an increased risk [19,31,34,35] with the GSTT1 null genotype, others no association [11,29,30], and only one suggests a decreased risk [24]. We observed no significant association with the GSTT1 polymorphism and bladder cancer risk.
###end p 45
###begin p 46
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. </italic>
The strengths of our study include the prospective design and the detailed collection of exposure information (i.e. cigarette smoking) prior to bladder cancer diagnosis. We were also able to formally assess and test gene-environment interactions. However, our study has a small sample size resulting in low power to detect minor to modest genotype-disease associations and gene-environment interactions, therefore such associations cannot be ruled out.
###end p 46
###begin title 47
Conclusion
###end title 47
###begin p 48
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
In summary, our data support the prior evidence that the GSTM1 null genotype and the NAT2 slow acetylation genotype may affect an individual's bladder cancer risk.
###end p 48
###begin title 49
Abbreviations
###end title 49
###begin p 50
###xml 72 74 72 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
HPFS, Health Professionals' Follow-Up Study; NHS, Nurses' Health Study; N-acetyltransferase, NAT; GSTT1, Glutathione S-transferase T1; GSTM1, Glutathione S-transferase M1; PAH, polycyclic aromatic hydrocarbons; OR, odds ratio; CI, confidence interval; LRT, likelihood ratio test
###end p 50
###begin title 51
Competing interests
###end title 51
###begin p 52
The author(s) declare that they have no competing interests.
###end p 52
###begin title 53
Authors' contributions
###end title 53
###begin p 54
MM carried out the data analysis and wrote the manuscript. DM and ID conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 54
###begin title 55
Pre-publication history
###end title 55
###begin p 56
The pre-publication history for this paper can be accessed here:
###end p 56
###begin p 57

###end p 57
###begin title 58
Acknowledgements
###end title 58
###begin p 59
###xml 231 243 <span type="species:ncbi:9606">participants</span>
We thank Jason Wong, Pati Soule, and Hardeep Ranu for their laboratory technical assistance and Carolyn Guo for statistical assistance. We also thank Deborah Boggs and Wendy Setiawan for their contributions. We are indebted to the participants in the Nurses' Health Study for their dedication and commitment. This work is supported by National Institute of Health Grants: CA55075, and CA87969, T32 CA 09001-28 (MM), a grant from the American Cancer Society: RSG-00-061-04-CCE (ID).
###end p 59
###begin article-title 60
The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review
###end article-title 60
###begin article-title 61
Bladder cancer: epidemiology, diagnosis, and management
###end article-title 61
###begin article-title 62
Bladder cancer, 1996
###end article-title 62
###begin article-title 63
Epidemiology and etiology of bladder cancer
###end article-title 63
###begin article-title 64
###xml 40 43 <span type="species:ncbi:9606">men</span>
Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies
###end article-title 64
###begin article-title 65
N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels
###end article-title 65
###begin article-title 66
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
###end article-title 66
###begin article-title 67
###xml 100 105 <span type="species:ncbi:9606">human</span>
Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder
###end article-title 67
###begin article-title 68
###xml 62 67 <span type="species:ncbi:9606">human</span>
Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis
###end article-title 68
###begin article-title 69
Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue
###end article-title 69
###begin article-title 70
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses
###end article-title 70
###begin article-title 71
Acetylator genotype and arylamine-induced carcinogenesis
###end article-title 71
###begin article-title 72
NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population
###end article-title 72
###begin article-title 73
###xml 58 63 <span type="species:ncbi:9606">human</span>
Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
###end article-title 73
###begin article-title 74
Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10
###end article-title 74
###begin article-title 75
Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians
###end article-title 75
###begin article-title 76
Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese
###end article-title 76
###begin article-title 77
Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking
###end article-title 77
###begin article-title 78
GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population
###end article-title 78
###begin article-title 79
The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction
###end article-title 79
###begin article-title 80
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
###end article-title 80
###begin article-title 81
###xml 30 35 <span type="species:ncbi:9606">human</span>
Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
###end article-title 81
###begin article-title 82
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review
###end article-title 82
###begin article-title 83
GSTT1-null genotype is a protective factor against bladder cancer
###end article-title 83
###begin article-title 84
###xml 34 39 <span type="species:ncbi:9606">human</span>
Distribution of ethylene oxide in human blood and its implications for biomonitoring
###end article-title 84
###begin article-title 85
Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
###end article-title 86
###begin article-title 87
Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis
###end article-title 87
###begin article-title 88
Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study
###end article-title 88
###begin article-title 89
Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk
###end article-title 89
###begin article-title 90
###xml 12 17 <span type="species:ncbi:9606">human</span>
The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer
###end article-title 90
###begin article-title 91
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer
###end article-title 91
###begin article-title 92
The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer
###end article-title 92
###begin article-title 93
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk
###end article-title 93
###begin article-title 94
Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder
###end article-title 94
###begin article-title 95
Androgen receptor polymorphisms and endometrial cancer risk
###end article-title 95
###begin article-title 96
N-acetyl transferase 2 genotypes, meat intake and breast cancer risk
###end article-title 96
###begin article-title 97
A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer
###end article-title 97
###begin article-title 98
Prospective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer
###end article-title 98
###begin article-title 99
Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility
###end article-title 99
###begin article-title 100
Folate, methionine, and alcohol intake and risk of colorectal adenoma
###end article-title 100
###begin article-title 101
SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes
###end article-title 101
###begin article-title 102
###xml 35 40 <span type="species:ncbi:9606">human</span>
Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
###end article-title 102
###begin article-title 103
###xml 11 16 <span type="species:ncbi:9606">human</span>
Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human acetyltransferase polymorphisms
###end article-title 104
###begin article-title 105
Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review
###end article-title 105
###begin article-title 106
Genetic variability in susceptibility and response to toxicants
###end article-title 106
###begin article-title 107
Aromatic amines and cancer
###end article-title 107
###begin title 108
Figures and Tables
###end title 108
###begin p 109
Selected population characteristics of bladder cancer cases and matched controls
###end p 109
###begin p 110
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
1 Cases and controls were matched on year of birth
###end p 110
###begin p 111
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
2 Among cigarette smokers
###end p 111
###begin p 112
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 66 71 <span type="species:ncbi:9606">women</span>
###xml 76 79 <span type="species:ncbi:9606">men</span>
Association between GSTT1 and GSTM1 and bladder cancer risk among women and men
###end p 112
###begin p 113
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
1 unconditional logistic regression adjusted for age and smoking status
###end p 113
###begin p 114
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
2 unconditional logistic regression adjusted for age, smoking status, and packyears of smoking
###end p 114
###begin p 115
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 64 69 <span type="species:ncbi:9606">women</span>
###xml 74 77 <span type="species:ncbi:9606">men</span>
Association between NAT1 and NAT2 and bladder cancer risk among women and men
###end p 115
###begin p 116
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
1 unconditional logistic regression adjusted for age and smoking status
###end p 116
###begin p 117
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
2 unconditional logistic regression adjusted for age, smoking status, and packyears of smoking
###end p 117

